eligibility_summary
Inclusion: Women 18–75 with epithelial ovarian/FT/peritoneal cancer, HER2+ (IHC 1–3+), 1–4 prior lines, no prior HER2 drugs, ECOG 0–1, measurable disease, >3‑mo survival, adequate organs, tumor tissue, not pregnant/using contraception. Exclusion: other histology, neuropathy ≥G2, bleeding risk, active CNS mets, GI obstruction/perforation, recent surgery/vaccine/trial, CV/thrombosis, uncontrolled comorbidities/autoimmune, active infection (HIV/HBV/HCV), recent cancers, allergy/substance abuse.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
NCT06420973 tests RC48 + carboplatin ± bevacizumab in platinum-sensitive recurrent epithelial ovarian/fallopian tube/primary peritoneal cancer with HER2 expression. Drugs and mechanisms (type): • RC48 (disitamab vedotin) – anti-HER2 antibody–drug conjugate, antibody binds HER2/ERBB2 on tumor cells, is internalized, and releases MMAE, a microtubule inhibitor, causing mitotic arrest/apoptosis. • Carboplatin – platinum cytotoxic chemotherapy, forms DNA intra/interstrand crosslinks, triggering DNA damage responses and cell death. • Bevacizumab – anti-VEGF-A monoclonal antibody, blocks VEGF/VEGFR signaling to inhibit angiogenesis. Cells/pathways targeted: • HER2-expressing tumor cells (ERBB2 signaling, microtubule cytoskeleton). • Proliferating tumor cells (DNA damage/crosslink repair pathways). • Tumor endothelial cells (VEGF-driven angiogenesis). Single-arm phase II: 6 q3w cycles then RC48 ± bevacizumab maintenance.